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Biochemical Study of a New Inhibitor-Resistant -Lactamase, SHV-84,
Produced by a Clinical Escherichia coli Strain
Inhibitor-resistant TEM (IRT) -lactamases derive from
TEM-1 or TEM-2 enzymes by point mutations in the corre-
sponding coding gene (http://www.lahey.org/studies). Inhibi-
tor-resistant SHV (IRS) -lactamases are less commonly iden-
tified than IRT enzymes, and mainly in Klebsiella pneumoniae
strains (3, 4, 5, 8, 9). In this study, we performed a phenotypic,
molecular, and biochemical characterization of a new IRS en-
zyme, SHV-84, produced by a clinical Escherichia coli strain.
E. coli INSRA4590 was isolated from a patient admitted in
1999 to Centro Hospitalar de Coimbra, Portugal. Antimicro-
bial susceptibility, isoelectric focusing for isoelectric point de-
termination, identification of -lactamase-encoding genes, and
extraction and purification of a new -lactamase were per-
formed as previously described (1, 7). Antimicrobial suscepti-
bility results were interpreted by using French Society of Mi-
crobiology criteria (2). E. coli INSRA4590 exhibited high-level
resistance to the penicillins tested (except piperacillin) and to
the combination of amoxicillin and clavulanic acid but was
susceptible to the combination of piperacillin and tazobactam
(Table 1); it was susceptible to all cephalosporins tested and to
aztreonam.
The clinical strain expressed SHV-1 with a pI of 7.6 and the
new SHV-84 -lactamase with a pI of 7.4, which differed from
SHV-1 by the amino acid substitution Lys234Arg. This muta-
tion has been described in other IRS enzymes, such as SHV-56
(5) and SHV-72 (also encountered in Portugal) (8), in which it
was associated with the substitution Leu35Gln and the substi-
tutions Ile8Phe and Ala146Val, respectively. The recombinant
SHV-encoding plasmid (pBK-SHV-84) and the corresponding
transformant E. coli DH5 were obtained as previously de-
scribed (8). The SHV-84-producing transformant DH5-
SHV-84 exhibited a -lactam resistance phenotype similar to
that of the clinical strain (Table 1), and the corresponding
-lactamase had a pI of 7.4.
The kinetic constants of the purified enzyme (99% pure;
data not shown) and the concentrations of inhibitors required
to inhibit enzyme activity by 50% (IC50s) were determined as
previously reported (6, 8) and compared with those of SHV-1.
Unlike SHV-72, SHV-84 showed a lower affinity for penicillins
(Km, 64 to 101 M) and decreased catalytic activity against
these antibiotics (kcat, 216 to 1,042 s
1) than SHV-1 (Km, 11 to
31 M; kcat, 220 to 1,937 s
1) (Table 1). In SHV-72, mutations
other than Lys234Arg might confer increased affinity of the
enzyme for penicillins, as well as better catalytic activity against
those antibiotics. SHV-84, like SHV-72, exhibited lower affinity
for cephalothin (Km, 169 to 141 M) than SHV-1. No hydro-
lysis of extended-spectrum cephalosporins was detected. How-
ever, SHV-84 was less susceptible to clavulanic acid (IC50, 2.21
M) than SHV-1 (IC50, 0.17 M), as observed for SHV-72
(IC50, 1.72 M) (Table 1) (8). The IC50 of tazobactam for
SHV-84 was 3.5-fold lower than that for SHV-1 (IC50s, 0.03
and 0.15 M, respectively).
In conclusion, this study underlines the importance of the
Lys234Arg substitution in resistance to clavulanic acid in na-
ture, since we demonstrate that this mutation alone is respon-
sible for decreased susceptibility to -lactamase inhibitors.
These results corroborate those previously obtained by molec-
ular dynamic simulation in a study using the model of the
mutant SHV-72 enzyme, in which the authors suggested a
change in the positioning of the Ser130 side chain induced by
Arg234 (8).
Nucleotide sequence accession number. The new blaSHV
nucleotide sequence was submitted to the EMBL Nucleotide
TABLE 1. MICs for clinical, transformant, and recipient E. coli strains and kinetic parameters of SHV-84 and SHV-1 -lactamases
Antimicrobial(s)
MIC (g/ml) for E. coli strain: Kinetic parameters of enzymea
DH5 DH5-SHV-1(pBK-SHV-1)b
DH5-SHV-
84(pBK-
SHV-84)b
INSRA4590
(SHV-84)
SHV-1c SHV-84
Km (M) kcat (s1)
kcat/Km
(M1  s1) Km (M) kcat (s
1) kcat/Km(M1  s1)
Penicillin G NDf ND ND ND 23 0.42 1,937  82 84.2 2.0 64  0.81 611  43 9.5  0.8
Amoxicillin 2 2,048 2,048 512 31 1.29 1,044  10 33.7 1.1 101  2.75 1,042  116 10.4 1.4
Amoxicillin 
CLAd
2 8 64 64 ND ND ND ND ND ND
Ticarcillin 2 1,024 4,096 4,096 11  3.40 220  49 20.0  1.7 83  5.97 216  20 2.5  0.01
Piperacillin 1 64 128 64 24 0.53 1,490  96 62.1 2.7 68  2.90 406  15 6.0  0.03
Piperacillin 
TAZe
1 2 2 4 ND ND ND ND ND ND
Cephalothin 1 16 8 8 40  1.46 128  33 3.2  0.8 169  0.31 4  0.3 0.02  0.002
Ceftazidime 0.06 0.5 0.25 0.25 142 3.18 0.1 NHg NH 0.1 NH
Cefotaxime 0.015 0.06 0.06 0.125 257 20.65 0.1 NH NH 0.1 NH
Aztreonam 0.015 0.125 0.03 0.03 ND ND ND ND ND ND
a Values are means  standard deviations.
b E. coli DH5-SHV-1 and E. coli DH5-SHV-84 were the transformants producing SHV-1 and SHV-84, respectively. The MICs for SHV-1 are from reference 8.
c The kinetic constants of SHV-1 are from reference 8.
d CLA, clavulanic acid at a fixed concentration of 2 g/ml.
e TAZ, tazobactam at a fixed concentration of 4 g/ml.
f ND, not determined.
g NH, not determinable because the hydrolysis rates were too low.
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Sequence Database as blaSHV-84 with accession number
AM087453.
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